Quotables
"There is no reason anyone would want a computer in their home."
Ken Olsen, chairman and founder of Digital Equipment Corporation ; 1977
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120130144 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR In one aspect, the present invention provides a method of treating lung cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one growth factor inhibitor. In another aspect, the present invention provides a method of trea... | 05/24/2012 |
| 20120107317 | USE OF CYTOPLASMIC C-MYC FOR REGULATING IMMUNE RESPONSES The subject invention provides novel uses of cytoplasmic c-Myc for modulation of innate immune responses. The invention is based, at least in part, on the surprising discovery that cytoplasmic c-Myc, instead of nuclear c-Myc, modulates pro-inflammatory immune responses ... | 05/03/2012 |
| 20120107306 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and me... | 05/03/2012 |
| 20120107391 | THERAPY OF PLATINUM-RESISTANT CANCER The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.... | 05/03/2012 |
| 20120107235 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the tre... | 05/03/2012 |
| 20120082663 | ANTI-CMET ANTAGONISTS The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... | 04/05/2012 |
| 20120082662 | ANTI-CMET ANTAGONISTS The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... | 04/05/2012 |
| 20120039889 | METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER CHARACTERIZED BY NDRG1-ERG FUSION An in depth analysis of prostate cancer prostatectomy samples which over-express the ERG oncogene led to the discovery of a novel gene translocation in prostate cancer, between the NDRG1 gene (N-myc downstream regulated gene 1) on chromosome 8 and the ERG oncogene on ch... | 02/16/2012 |
| 20120039888 | Methods Of Inhibiting Inflammation-Associated Tissue Damage By Inhibiting Neutrophil Activity The present invention relates to compositions and methods for treating inflammation-associated tissue damage, and particularly transfusion-associated, disorders, by inhibiting or reducing E-selectin mediated signal transduction pathways, such as E-selectin mediated acti... | 02/16/2012 |
| 20120039885 | COMPOSITION AND METHOD FOR CANCER TREATMENT Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.... | 02/16/2012 |
| 20120034213 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-E... | 02/09/2012 |
| 20120027763 | Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1 Antibody for targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1, is disclosed. The antibodies, TBL-CLN1, are monoclonal antibodies which can specifically target and bind to the epitope of SEQ ID NO:1 expressed on cancer cells which ... | 02/02/2012 |
| 20120014872 | Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.... | 01/19/2012 |
| 20120003213 | Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic a... | 01/05/2012 |
| 20110318351 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treat... | 12/29/2011 |
| 20110313230 | SPECIFIC BINDING PROTEINS AND USES THEREOF The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the e... | 12/22/2011 |
| 20110311538 | INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the r... | 12/22/2011 |
| 20110300146 | ANTI-CMET ANTAGONISTS
| 12/08/2011 |
| 20110293614 | ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.... | 12/01/2011 |
| 20110293615 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogue... | 12/01/2011 |
| 20110274688 | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST NEU Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumo... | 11/10/2011 |
| 20110262358 | MOLECULAR MARKER FOR CANCER STEM CELL A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is d... | 10/27/2011 |
| 20110262436 | TREATMENT METHOD The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.... | 10/27/2011 |
| 20110256142 | NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention... | 10/20/2011 |
| 20110250165 | Antibodies against CXCR4 and Methods of Use Thereof The invention provides human monoclonal antibodies, scFv antibodies, scFv-Fc fusions, a dAb (domain antibodies), Fab, Fab′ and F(ab)′2 fragments, single chain antibodies and/or minibodies that specifically bind to CXCR4. Also provide... | 10/13/2011 |
| 20110239316 | ANTI-cMET ANTIBODY Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprisi... | 09/29/2011 |
| 20110229406 | Material and methods for treating or preventing HER-3 associated diseases Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the seco... | 09/22/2011 |
| 20110229478 | ERBB3 BASED METHODS AND COMPOSITIONS FOR TREATING NEOPLASMS The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying neoplasm in a mammal using an ErbB-3 protein, a nucleic a... | 09/22/2011 |
| 20110229469 | METHODS FOR THE TREATMENT OF CANCER Methods for treating cancer with at least one HGF-Met inhibitor and at least one EGFR inhibitor are provided... | 09/22/2011 |
| 20110229479 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had ... | 09/22/2011 |
| 20110229480 | PTA072 PROTEIN The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer, kidney cancer, pancreatic cancer or prostate cancer, for monitoring the effectiveness of B-cell ... | 09/22/2011 |
| 20110223171 | Methods and Compositions for the Diagnosis and Treatment of Cyclin A-1 Associated Conditions The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting cyclin A1.... | 09/15/2011 |
| 20110217305 | ANTI-HER2 ANTIBODIES AND COMPOSITIONS The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions comprising at least two of said recombinant anti-HER2 antibodies, and use of the antibodies and antibody compos... | 09/08/2011 |
| 20110200525 | VHH ANTIBODY FRAGMENTS FOR USE IN THE DETECTION AND TREATMENT OF CANCER The presently disclosed subject matter provides ligands for detecting and imaging cancer cells and tumors, and for guided delivery of an active agent to cancer cells and tumors. In some embodiments the ligands comprise an antibody fragment, wherein the antibody fragment... | 08/18/2011 |
| 20110200598 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprisi... | 08/18/2011 |
| 20110189186 | AFFECTING BONE RELATED CONDITIONS USING CD68 BLOCKING AGENTS Methods of treating, reducing, and/or preventing cancer metastasis to bone using CD68 blocking agents are provided. For example, the methods can be used to reduce breast cancer metastasis to bone. Also provided are methods of treating, reducing, and/or preventing bone r... | 08/04/2011 |
| 20110189185 | Method for Predicting Responsiveness to a Treatment With an Anti-HER2 Antibody The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with an anti-HER2 blocking agent, such as trastuzumab, which method comprises determining the expression level of at least 4 genes in a biological sample of sai... | 08/04/2011 |
| 20110189085 | Antibody Therapy The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... | 08/04/2011 |
| 20110176996 | COMPOSITIONS AND METHODS FOR CANCER MANAGEMENT USING ANTIBODIES BINDING TO NUCLEOTIDE SALVAGE PATHWAY ENZYMES AND COMPLEXES THEREOF Compositions and methods are provided for the diagnosis, treatment, and medical management of cancers. The methods include the use of antibodies and other binding molecules that specifically bind to one or more nucleotide salvage pathway enzymes (SPEs) selected from the... | 07/21/2011 |
| 20110177077 | PAX 5 MONOCLONAL ANTIBODY The present invention relates to novel anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. In particular the invention relates to an antibody, antigen binding fragment or recombinant protein th... | 07/21/2011 |
